About
David is President, CEO, and Director of Indigo. He is a serial entrepreneur who has founded and built three innovative companies in the last 18 years, leading the last two through successful IPOs and to multi-billion dollar market capitalizations, and raising over $750 million, while generating significant returns for investors. David was most recently CEO and Co-Founder of Anacor Pharmaceuticals (NASDAQ: ANAC), a biopharmaceutical company discovering and developing novel small-molecule therapeutics to treat infectious and inflammatory diseases. David previously co-founded and served as CEO of Chemdex (NASDAQ: CMDX), later creating its parent company Ventro Corporation (NASDAQ: VNTR), a business-to-business marketplace focused on the life sciences industry. At its peak, Ventro was valued at $11 billion and was later sold to Nexprise. David is Founder and Chairman of the San Francisco-based digital health startup, Farewell, and a Director of the human microbiome company, Epiva. In 2
Position in the VCSift Database
- • 22 investors hold the Chairman and Co-founder role in VCSift. David Perry is one of them.
- • 491 investors are based in Cambridge, Massachusetts, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Stages
- seed
- Location
- Cambridge, US
Contact Information
Find more investors like David
Search Investors